A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
- Disease/Condition
- Diabetes Mellitus, Type 2
- Drug/Device/Intervention
- Insulin Lispro-aabc
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Eli Lilly and Company
- Location
- Vizag,Royapuram,Ahmedabad,Bengaluru,Pune,Pune,Bikaner,Jaipur,Coimbatore,Hyderabad,Kanpur,Kolkata, India
- Phase
- Phase 4
- Start date
- Apr 18, 2024
- End date
- Jul 01, 2025
- Enrollment
- 112 participants
Percentage of Participants with at least 1 Episode of Hypoglycemia
The purpose of this study is to assess the safety of insulin lispro-aabc in adult
 participants with Type 2 diabetes mellitus in India.
 
 The study will last about 33 weeks for each participant, including screening (1 week),
 Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06370715
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06370715 through Pure Global AI's free database. This Phase 4 trial is sponsored by Eli Lilly and Company and is currently Recruiting. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 112 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.